A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objectives: To develop a nomogram for estimating the glycated haemoglobin (HbA1c) response to different dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes. Design: A systematic review and meta-analysis of randomised controlled trials (RCTs) of DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and alogliptin) on HbA1c were conducted. Electronic searches were carried out up to December 2013. Trials were included if they were carried out on participants with type 2 diabetes, lasted at least 12 weeks, included at least 30 participants and had a final assessment of HbA1c. A random effect model was used to pool data. A nomogram was used to represent results of the metaregression model. Participants: Adults with type 2 diabetes. Interventions: Any DPP-4 inhibitor (vildagliptin, sitagliptin, saxagliptin, linagliptin or alogliptin). Outcome measures: The HbA1c response to each DPP-4 inhibitor within 1 year of therapy. Results: We screened 928 citations and reviewed 98 articles reporting 98 RCTs with 100 arms in 24 163 participants. There were 26 arms with vildagliptin, 37 with sitagliptin, 13 with saxagliptin, 13 with linagliptin and 11 with alogliptin. For all 100 arms, the mean baseline HbA1c value was 8.05% (64 mmol/mol); the decrease of HbA1c from baseline was −0.77% (95% CI −0.82 to −0.72%), with high heterogeneity (I 2=96%). Multivariable metaregression model that included baseline HbA1c, type of DPP-4 inhibitor and fasting glucose explained 58% of variance between studies, with no significant interaction between them. Other factors, including age, previous diabetes drugs and duration of treatment added low predictive power (<1%). The nomogram estimates the absolute HbA1c reduction from baseline using the type of DPP-4 inhibitor, baseline values of HbA1c and fasting glucose. Conclusions: Baseline HbA1c level and fasting glucose explain most of the variance in HbA1c change in response to DPP-4 inhibitors: each increase of 1.0% units HbA1c provides a 0.4–0.5% units greater fall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · cited 1×
“9 Although RCTs are the most reliable methods of determining the effects of treatment, to be clinically useful, their result must also be relevant to definable groups of patients in a particular clinical setting in routine practice (generalisability).(10) The inherent difficulty of applying trial data to individual pa…”
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Controlling the risk of spurious findings from meta-regression
Higgins, J. P. T., & Thompson, S. G. (2004) · Statistics in Medicine · doi:10.1002/sim.1752 · Cited by 1,267 · cited 1×
“Permutation test (using 1000 reallocations) was used for assessing the true statistical significance of an observed metaregression finding.(24) How much the metaregression model explained heterogeneity of the effect among studies was quantified by the percentage reduction of between-studies variability.”
MethodKaragiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435 · cited 1×
“A number of randomised controlled trials (RCTs) provided evidence of improved glycaemic control with the family of the dipeptidyl peptidase-4 (DPP-4) inhibitors, with modest risk of hypoglycaemia, and no weight gain.(6) In a descriptive, cross-sectional analysis of data using the IMS Health National Disease and Therap…”
Background
Cited by
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
“For gliptins there is no evidence of sex differences in HbA1c reduction [116].”
BackgroundGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Muscogiuri, G., Barrea, L., Di Somma, C., Altieri, B., Vecchiarini, M., Orio, F., Spinosa, T., Colao, A., & Savastano, S. (2019) · Hormones · doi:10.1007/s42000-018-0090-9 · Cited by 48
Ueno, H., Tsuchimochi, W., Wang, H.-W., Yamashita, E., Tsubouchi, C., Nagamine, K., Sakoda, H., & Nakazato, M. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0113-3 · Cited by 38
“77% after 1 year of treatment [3], and randomized trials to evaluate their cardiovascular safety are in progress [4].”
Background
Metadata
- Authors
- Esposito, K., Chiodini, P., Maiorino, M. I., Capuano, A., Cozzolino, D., Petrizzo, M., Bellastella, G., & Giugliano, D.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2015-02
- Volume
- 5
- Issue
- 2
- Pages
- e005892
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2146774087
- Cited by
- 77
- References
- 8
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. https://app.cochat.ai/papers/10.1136/bmjopen-2014-005892
- The paper
- Esposito, K., Chiodini, P., Maiorino, M. I., Capuano, A., Cozzolino, D., Petrizzo, M., Bellastella, G., & Giugliano, D. (2015). A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. https://doi.org/10.1136/bmjopen-2014-005892
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.